Durable Medical Equipment Market

Publisher Grand View Research

Published Feb 03, 2026

Length 90 Pages

SKU # GV21005559

Description

Size, Share & Trends Analysis Report By Product (Personal Mobility Devices, Bathroom Safety Devices And Medical Furniture), By End Use (Hospitals, Nursing Homes, Home Healthcare), By Region, And Segment Forecasts, 2026 - 2033

Durable Medical Equipment Market Summary

The global durable medical equipment market size was valued at USD 246.02 billion in 2025 and is projected to reach USD 379.82 billion by 2033, growing at a CAGR of 5.70% from 2026 to 2033. The industry is driven by the rising prevalence of chronic diseases, an aging population, and increasing demand for long-term and home-based care.

Technological advancements such as smart, connected, and lightweight medical devices further enhance patient convenience and treatment efficiency. Furthermore, growing healthcare awareness and supportive reimbursement policies are accelerating market adoption. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) and asthma are the most common chronic respiratory diseases (CRDs), with COPD accounting for nearly 80% of CRD-related deaths. With an aging global population and multiple health challenges, COPD cases are projected to rise by 23% worldwide by 2050, disproportionately affecting women and individuals in low- and middle-income countries.

The growing prevalence of chronic diseases such as diabetes, cardiovascular disorders, respiratory conditions, and mobility-limiting illnesses is a major driver of the DME market. These conditions often require long-term management, continuous monitoring, and supportive care, increasing demand for equipment such as glucose monitors, oxygen concentrators, mobility aids, and therapeutic devices. As the global prevalence of chronic diseases rises, patients depend on DME to manage symptoms, improve quality of life, and reduce hospital visits. This sustained need for ongoing care solutions continues to fuel growth in the DME market.

Cardiovascular disease cases are increasing due to this rising demand for long-term monitoring and therapeutic devices, such as blood pressure monitors, oxygen concentrators, and mobility aids. The need for continuous care, rehabilitation, and home-based management of CVD patients supports DME adoption.

Global Durable Medical Equipment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global durable medical equipment market report on the basis of product, end use, and region:

Product Outlook (Revenue, USD Million; 2021 - 2033)
Personal Mobility Devices
Wheelchairs
Scooters
Walker and Rollators
Canes and Crutches
Door Openers
Other Devices
Bathroom Safety Devices and Medical Furniture
Commodes and Toilets
Mattress & Bedding Devices
Monitoring and Therapeutic Devices
Blood Sugar Monitors
Continuous Passive Motion (CPM)
Infusion Pumps
Nebulizers
Oxygen Equipment
Continuous Positive Airway Pressure (CPAP)
Suction Pumps
Traction Equipment
Others Equipment
End Use Outlook (Revenue, USD Million; 2021 - 2033)
Hospitals
Nursing Homes
Home Healthcare
Other End-user
Regional Outlook (Revenue, USD Million; 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait

Please note The report will be delivered in 2-3 business days upon order notification.

Chapter 1. Methodology and Scope: 1.1. Market Segmentation and Scope; 1.1.1. Product; 1.1.2. End Use; 1.1.3. Regional scope; 1.1.4. Estimates and forecast timeline; 1.2. Market Definitions; 1.3. Research Methodology; 1.4. Information Procurement; 1.4.1. Purchased Database; 1.4.2. GVR’s Internal Database; 1.5. Details of primary research; 1.5.1. Data for primary interviews in North America; 1.5.2. Data for primary interviews in Europe; 1.5.3. Data for primary interviews in Asia Pacific; 1.5.4. Data for primary interviews in Latin America; 1.5.5. Data for Primary interviews in MEA; 1.6. Market Formulation & Validation; 1.7. Model Details; 1.7.1. Commodity flow analysis (Model 1); 1.7.1.1. Approach 1: Commodity flow approach; 1.7.2. Volume price analysis (Model 2); 1.7.2.1. Approach 2: Volume price analysis; 1.8. Research Scope and Assumptions; 1.8.1. List of Secondary Sources; 1.8.2. List of Primary Sources; 1.8.3. Objectives
Chapter 2. Executive Summary: 2.1. Market Outlook; 2.2. Segment Outlook; 2.3. Competitive Insights
Chapter 3. Durable Medical Equipment Market Variables, Trends, & Scope: 3.1. Market Lineage Outlook; 3.1.1. Parent Market Outlook; 3.1.2. Related/Ancillary Market Outlook; 3.2. Market Dynamics; 3.2.1. Market Drivers Analysis; 3.2.1.1. Growth in Chronic Diseases; 3.2.1.2. Shift from Hospital-Based Care to Home-Based Care; 3.2.1.3. Growing geriatric population; 3.2.2. Market Restraints Analysis; 3.2.2.1. High Equipment Costs; 3.2.2.2. Limited Reimbursement; 3.2.3. Market Opportunity Analysis; 3.2.3.1. Post-Surgery & Rehabilitation Care; 3.2.3.2. Technological Advancement and Product Innovation; 3.2.3.3. Smart, Connected, and Data-Enabled Equipment; 3.2.3.4. Emerging Market Expansion; 3.2.4. Market Challenge Analysis; 3.2.4.1. Skilled Workforce Shortage; 3.3. Durable Medical Equipment Market Analysis Tools; 3.3.1. Porter’s Analysis; 3.3.1.1. Bargaining power of the suppliers; 3.3.1.2. Bargaining power of the buyers; 3.3.1.3. Threats of substitution; 3.3.1.4. Threats from new entrants; 3.3.1.5. Competitive rivalry; 3.3.2. PESTEL Analysis; 3.3.2.1. Political landscape; 3.3.2.2. Economic and Social landscape; 3.3.2.3. Technological landscape; 3.3.2.4. Environmental landscape; 3.3.2.5. Legal landscape
Chapter 4. Durable Medical Equipment Market: Product Estimates & Trend Analysis: 4.1. Segment Dashboard; 4.2. Global Durable Medical Equipment Market: Product Movement Analysis, 2025 & 2033 (USD Million); 4.3. Global Durable Medical Equipment Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million); 4.4. Personal Mobility Devices; 4.4.1. Personal mobility devices market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.4.2. Wheelchairs; 4.4.2.1. Wheelchairs market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.4.3. Scooters; 4.4.3.1. Scooters market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.4.4. Walker and rollators; 4.4.4.1. Walker and rollators market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.4.5. Canes and crutches; 4.4.5.1. Canes and crutches market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.4.6. Door Openers; 4.4.6.1. Door openers market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.4.7. Other Devices; 4.4.7.1. Other devices market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.5. Bathroom Safety Devices and Medical Furniture; 4.5.1. Bathroom safety devices and medical furniture market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.5.2. Commodes and toilets; 4.6.2.1. Commodes and toilets market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.5.3. Mattress & bedding devices; 4.6.3.1. Mattress & bedding devices market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.6. Monitoring and Therapeutic Devices; 4.6.1. Monitoring and therapeutic devices market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.6.2. Blood sugar monitors; 4.6.2.1. Blood sugar monitors market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.6.3. Continuous Passive Motion (CPM); 4.6.3.1. Continuous Passive Motion (CPM) market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.6.4. Infusion pumps; 4.6.4.1. Infusion pumps market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.6.5. Nebulizers; 4.6.5.1. Nebulizers market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.6.6. Oxygen equipment; 4.6.6.1. Oxygen equipment market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.6.7. Continuous positive airway pressure (CPAP); 4.6.7.1. Continuous positive airway pressure (CPAP) market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.6.8. Suction pumps; 4.6.8.1. Suction pumps market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.6.9. Traction equipment; 4.6.9.1. Traction equipment market revenue estimates and forecasts, 2021 - 2033 (USD Million); 4.6.10. Others equipment; 4.6.10.1. Others equipment market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 5. Durable Medical Equipment Market: End Use Estimates & Trend Analysis: 5.1. Segment Dashboard; 5.2. Global Durable Medical Equipment Market: End use, Movement Analysis, 2025 & 2033 (USD Million); 5.3. Global Durable Medical Equipment Market Size & Trend Analysis, by End use, 2021 to 2033 (USD Million); 5.4. Hospitals; 5.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million); 5.5. Nursing Homes; 5.5.1. Nursing homes market revenue estimates and forecasts, 2021 - 2033 (USD Million); 5.6. Home Healthcare; 5.6.1. Home healthcare market revenue estimates and forecasts, 2021 - 2033 (USD Million); 5.7. Other end-user; 5.7.1. Other end-user market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 6. Durable Medical Equipment Market: Regional Estimates & Trend Analysis by Product, and End Use: 6.1. Regional Dashboard; 6.2. Market Size and Trend Analysis, 2021 to 2033; 6.3. North America; 6.3.1. North America durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.3.2. U.S.; 6.3.2.1. Key country dynamics; 6.3.2.2. Competitive scenario; 6.3.2.3. Regulatory framework; 6.3.2.4. Reimbursement scenario; 6.3.2.5. U.S. durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.3.3. Canada; 6.3.3.1. Key country dynamics; 6.3.3.2. Competitive scenario; 6.3.3.3. Regulatory framework; 6.3.3.4. Reimbursement scenario; 6.3.3.5. Canada durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.3.4. Mexico; 6.3.4.1. Key country dynamics; 6.3.4.2. Competitive scenario; 6.3.4.3. Regulatory framework; 6.3.4.4. Reimbursement scenario; 6.3.4.5. Mexico durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.4. Europe; 6.4.1. Europe durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.4.2. UK; 6.4.2.1. Key country dynamics; 6.4.2.2. Competitive scenario; 6.4.2.3. Regulatory framework; 6.4.2.4. Reimbursement scenario; 6.4.2.5. UK durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.4.3. Germany; 6.4.3.1. Key country dynamics; 6.4.3.2. Competitive scenario; 6.4.3.3. Regulatory framework; 6.4.3.4. Reimbursement scenario; 6.4.3.5. Germany durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.4.4. France; 6.4.4.1. Key country dynamics; 6.4.4.2. Competitive scenario; 6.4.4.3. Regulatory framework; 6.4.4.4. Reimbursement scenario; 6.4.4.5. France durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.4.5. Italy; 6.4.5.1. Key country dynamics; 6.4.5.2. Competitive scenario; 6.4.5.3. Regulatory framework; 6.4.5.4. Reimbursement scenario; 6.4.5.5. Italy durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.4.6. Spain; 6.4.6.1. Key country dynamics; 6.4.6.2. Competitive scenario; 6.4.6.3. Regulatory framework; 6.4.6.4. Reimbursement scenario; 6.4.6.5. Spain durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.4.7. Sweden; 6.4.7.1. Key country dynamics; 6.4.7.2. Competitive scenario; 6.4.7.3. Regulatory framework; 6.4.7.4. Reimbursement scenario; 6.4.7.5. Sweden durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.4.8. Denmark; 6.4.8.1. Key country dynamics; 6.4.8.2. Competitive scenario; 6.4.8.3. Regulatory framework; 6.4.8.4. Reimbursement scenario; 6.4.8.5. Denmark durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.4.9. Norway; 6.4.9.1. Key country dynamics; 6.4.9.2. Competitive scenario; 6.4.9.3. Regulatory framework; 6.4.9.4. Reimbursement scenario; 6.4.9.5. Norway durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.5. Asia Pacific; 6.5.1. Asia Pacific durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.5.2. China; 6.5.2.1. Key country dynamics; 6.5.2.2. Competitive scenario; 6.5.2.3. Regulatory framework; 6.5.2.4. Reimbursement scenario; 6.5.2.5. China durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.5.3. Japan; 6.5.3.1. Key country dynamics; 6.5.3.2. Competitive scenario; 6.5.3.3. Regulatory framework; 6.5.3.4. Reimbursement scenario; 6.5.3.5. Japan durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.5.4. India; 6.5.4.1. Key country dynamics; 6.5.4.2. Competitive scenario; 6.5.4.3. Regulatory framework; 6.5.4.4. Reimbursement scenario; 6.5.4.5. India durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.5.5. South Korea; 6.5.5.1. Key country dynamics; 6.5.5.2. Competitive scenario; 6.5.5.3. Regulatory framework; 6.5.5.4. Reimbursement scenario; 6.5.5.5. South Korea durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.5.6. Australia; 6.5.6.1. Key country dynamics; 6.5.6.2. Competitive scenario; 6.5.6.3. Regulatory framework; 6.5.6.4. Reimbursement scenario; 6.5.6.5. Australia durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.5.7. Thailand; 6.5.7.1. Key country dynamics; 6.5.7.2. Competitive scenario; 6.5.7.3. Regulatory framework; 6.5.7.4. Reimbursement scenario; 6.5.7.5. Thailand durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.6. Latin America; 6.6.1. Latin America durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.6.2. Brazil; 6.6.2.1. Key country dynamics; 6.6.2.2. Competitive scenario; 6.6.2.3. Regulatory framework; 6.6.2.4. Reimbursement scenario; 6.6.2.5. Brazil durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.6.3. Argentina; 6.6.3.1. Key country dynamics; 6.6.3.2. Competitive scenario; 6.6.3.3. Regulatory framework; 6.6.3.4. Reimbursement scenario; 6.6.3.5. Argentina durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.7. Middle East and Africa; 6.7.1. Middle East and Africa durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.7.2. South Africa; 6.7.2.1. Key country dynamics; 6.7.2.2. Competitive scenario; 6.7.2.3. Regulatory framework; 6.7.2.4. Reimbursement scenario; 6.7.2.5. South Africa durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.7.3. Saudi Arabia; 6.7.3.1. Key country dynamics; 6.7.3.2. Competitive scenario; 6.7.3.3. Regulatory framework; 6.7.3.4. Reimbursement scenario; 6.7.3.5. Saudi Arabia durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.7.4. UAE; 6.7.4.1. Key country dynamics; 6.7.4.2. Competitive scenario; 6.7.4.3. Regulatory framework; 6.7.4.4. Reimbursement scenario; 6.7.4.5. UAE durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million); 6.7.5. Kuwait; 6.7.5.1. Key country dynamics; 6.7.5.2. Competitive scenario; 6.7.5.3. Regulatory framework; 6.7.5.4. Reimbursement scenario; 6.7.5.5. Kuwait durable medical equipment market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape: 7.1. Recent Developments & Impact Analysis by Key Market Participants; 7.2. Company Categorization; 7.3. Company Market Share Analysis, 2025; 7.4. Company Heat Map Analysis; 7.5. Strategy Mapping; 7.5.1. Expansion; 7.5.2. Mergers & Acquisition; 7.5.3. Partnerships & Collaborations; 7.5.4. New Product Launches; 7.5.5. Research And Development; 7.5.6. Company Profiles; 7.5.7. Invacare Corporation; 7.5.7.1. Company overview; 7.5.7.2. Financial performance; 7.5.7.3. Product Benchmarking; 7.5.7.4. Strategic initiatives; 7.5.8. Arjo; 7.5.8.1. Company overview; 7.5.8.2. Financial performance; 7.5.8.3. Product Benchmarking; 7.5.8.4. Strategic initiatives; 7.5.9. Stryker Corporation; 7.5.9.1. Company overview; 7.5.9.2. Financial performance; 7.5.9.3. Product Benchmarking; 7.5.9.4. Strategic initiatives; 7.5.10. Hill Rom, Inc.; 7.5.10.1. Company overview; 7.5.10.2. Financial performance; 7.5.10.3. Product Benchmarking; 7.5.10.4. Strategic initiatives; 7.5.11. Drive Medical; 7.5.11.1. Company overview; 7.5.11.2. Financial performance; 7.5.11.3. Product Benchmarking; 7.5.11.4. Strategic initiatives; 7.5.12. GF Health Products, Inc.; 7.5.12.1. Company overview; 7.5.12.2. Financial performance; 7.5.12.3. Product Benchmarking; 7.5.12.4. Strategic initiatives; 7.5.13. Sunrise Medical; 7.5.13.1. Company overview; 7.5.13.2. Financial performance; 7.5.13.3. Product Benchmarking; 7.5.13.4. Strategic initiatives; 7.5.14. Medline Industries; 7.5.14.1. Company overview; 7.5.14.2. Financial performance; 7.5.14.3. Product Benchmarking; 7.5.14.4. Strategic initiatives; 7.5.15. Carex Health Brands, Inc; 7.5.15.1. Company overview; 7.5.15.2. Financial performance; 7.5.15.3. Product Benchmarking; 7.5.15.4. Strategic initiatives; 7.5.16. BD; 7.5.16.1. Company overview; 7.5.16.2. Financial performance; 7.5.16.3. Product Benchmarking; 7.5.16.4. Strategic initiatives; 7.5.17. GE HealthCare; 7.5.17.1. Company overview; 7.5.17.2. Financial performance; 7.5.17.3. Product Benchmarking; 7.5.17.4. Strategic initiatives; 7.5.18. Medtronic; 7.5.18.1. Company overview; 7.5.18.2. Financial performance; 7.5.18.3. Product Benchmarking; 7.5.18.4. Strategic initiatives; 7.5.19. Compass Health Brands; 7.5.19.1. Company overview; 7.5.19.2. Financial performance; 7.5.19.3. Product Benchmarking; 7.5.19.4. Strategic initiatives; 7.5.20. Getinge AB; 7.5.20.1. Company overview; 7.5.20.2. Financial performance; 7.5.20.3. Product Benchmarking; 7.5.20.4. Strategic initiatives; 7.5.21. Resmed Inc.; 7.5.21.1. Company overview; 7.5.21.2. Financial performance; 7.5.21.3. Product Benchmarking; 7.5.21.4. Strategic initiatives; 7.5.22. Cardinal Health; 7.5.22.1. Company overview; 7.5.22.2. Financial performance; 7.5.22.3. Product Benchmarking; 7.5.22.4. Strategic initiatives; 7.5.23. Drive DeVilbiss Healthcare; 7.5.23.1. Company overview; 7.5.23.2. Financial performance; 7.5.23.3. Product Benchmarking; 7.5.23.4. Strategic initiatives; 7.5.24. NOVA Medical Products; 7.5.24.1. Company overview; 7.5.24.2. Financial performance; 7.5.24.3. Product Benchmarking; 7.5.24.4. Strategic initiatives; 7.5.25. Kaye Products, Inc.; 7.5.25.1. Company overview; 7.5.25.2. Financial performance; 7.5.25.3. Product Benchmarking; 7.5.25.4. Strategic initiatives; 7.5.26. Karman Healthcare, Inc.; 7.5.26.1. Company overview; 7.5.26.2. Financial performance; 7.5.26.3. Product Benchmarking; 7.5.26.4. Strategic initiatives; 7.5.27. Numotion; 7.5.27.1. Company overview; 7.5.27.2. Financial performance; 7.5.27.3. Product Benchmarking; 7.5.27.4. Strategic initiatives; 7.5.28. Pride Mobility Products Corporation; 7.5.28.1. Company overview; 7.5.28.2. Financial performance; 7.5.28.3. Product Benchmarking; 7.5.28.4. Strategic initiatives; 7.5.29. Inogen, Inc.; 7.5.29.1. Company overview; 7.5.29.2. Financial performance; 7.5.29.3. Product Benchmarking; 7.5.29.4. Strategic initiatives; 7.5.30. CAIRE, Inc. (Niterra Group); 7.5.30.1. Company overview; 7.5.30.2. Financial performance; 7.5.30.3. Product Benchmarking; 7.5.30.4. Strategic initiatives; 7.5.31. Portable Oxygen Solutions; 7.5.31.1. Company overview; 7.5.31.2. Financial performance; 7.5.31.3. Product Benchmarking; 7.5.31.4. Strategic initiatives; 7.5.32. Rhythm Healthcare, LLC; 7.5.32.1. Company overview; 7.5.32.2. Financial performance; 7.5.32.3. Product Benchmarking; 7.5.32.4. Strategic initiatives; 7.5.33. MedaCure Inc.; 7.5.33.1. Company overview; 7.5.33.2. Financial performance; 7.5.33.3. Product Benchmarking; 7.5.33.4. Strategic initiatives; 7.5.34. Thermo Fisher Scientific, Inc.; 7.5.34.1. Company overview; 7.5.34.2. Financial performance; 7.5.34.3. Product Benchmarking; 7.5.34.4. Strategic initiatives; 7.5.35. Abbott; 7.5.35.1. Company overview; 7.5.35.2. Financial performance; 7.5.35.3. Product Benchmarking; 7.5.35.4. Strategic initiatives; 7.5.36. F. Hoffmann-La Roche Ltd.; 7.5.36.1. Company overview; 7.5.36.2. Financial performance; 7.5.36.3. Product Benchmarking; 7.5.36.4. Strategic initiatives; 7.5.37. Biotronic; 7.5.37.1. Company overview; 7.5.37.2. Financial performance; 7.5.37.3. Product Benchmarking; 7.5.37.4. Strategic initiatives; 7.5.38. Ascensia Diabetes Care Holdings AG; 7.5.38.1. Company overview; 7.5.38.2. Financial performance; 7.5.38.3. Product Benchmarking; 7.5.38.4. Strategic initiatives; 7.5.39. Byram Healthcare Centers, Inc. (Owens & Minor); 7.5.39.1. Company overview; 7.5.39.2. Financial performance; 7.5.39.3. Product Benchmarking; 7.5.39.4. Strategic initiatives; 7.5.40. Novo Nordisk; 7.5.40.1. Company overview; 7.5.40.2. Financial performance; 7.5.40.3. Product Benchmarking; 7.5.40.4. Strategic initiatives; 7.5.41. Insulet Corporation; 7.5.41.1. Company overview; 7.5.41.2. Financial performance; 7.5.41.3. Product Benchmarking; 7.5.41.4. Strategic initiatives; 7.5.42. Baxter; 7.5.42.1. Company overview; 7.5.42.2. Financial performance; 7.5.42.3. Product Benchmarking; 7.5.42.4. Strategic initiatives; 7.5.43. B. Braun SE; 7.5.43.1. Company overview; 7.5.43.2. Financial performance; 7.5.43.3. Product Benchmarking; 7.5.43.4. Strategic initiatives; 7.5.44. Micrel Medical Devices SA; 7.5.44.1. Company overview; 7.5.44.2. Financial performance; 7.5.44.3. Product Benchmarking; 7.5.44.4. Strategic initiatives; 7.5.45. Boston Scientific Corporation; 7.5.45.1. Company overview; 7.5.45.2. Financial performance; 7.5.45.3. Product Benchmarking; 7.5.45.4. Strategic initiatives; 7.5.46. Tandem Diabetes Care, Inc.; 7.5.46.1. Company overview; 7.5.46.2. Financial performance; 7.5.46.3. Product Benchmarking; 7.5.46.4. Strategic initiatives; 7.5.47. Moog, Inc.; 7.5.47.1. Company overview; 7.5.47.2. Financial performance; 7.5.47.3. Product Benchmarking; 7.5.47.4. Strategic initiatives; 7.5.48. IRadimed Corporation; 7.5.48.1. Company overview; 7.5.48.2. Financial performance; 7.5.48.3. Product Benchmarking; 7.5.48.4. Strategic initiatives; 7.5.49. Koninklijke Philips N.V.; 7.5.49.1. Company overview; 7.5.49.2. Financial performance; 7.5.49.3. Product Benchmarking; 7.5.49.4. Strategic initiatives; 7.5.50. Siemens Medical Solutions USA, Inc.; 7.5.50.1. Company overview; 7.5.50.2. Financial performance; 7.5.50.3. Product Benchmarking; 7.5.50.4. Strategic initiatives; 7.5.51. Essity; 7.5.51.1. Company overview; 7.5.51.2. Financial performance; 7.5.51.3. Product Benchmarking; 7.5.51.4. Strategic initiatives; 7.5.52. Coloplast Corporation; 7.5.52.1. Company overview; 7.5.52.2. Financial performance; 7.5.52.3. Product Benchmarking; 7.5.52.4. Strategic initiatives; 7.5.53. Paul Hartmann AG; 7.5.53.1. Company overview; 7.5.53.2. Financial performance; 7.5.53.3. Product Benchmarking; 7.5.53.4. Strategic initiatives; 7.5.54. Hollister Incorporated; 7.5.54.1. Company overview; 7.5.54.2. Financial performance; 7.5.54.3. Product Benchmarking; 7.5.54.4. Strategic initiatives; 7.5.55. Convatec Group PLC; 7.5.55.1. Company overview; 7.5.55.2. Financial performance; 7.5.55.3. Product Benchmarking; 7.5.55.4. Strategic initiatives; 7.5.56. Enovis Corporation; 7.5.56.1. Company overview; 7.5.56.2. Financial performance; 7.5.56.3. Product Benchmarking; 7.5.56.4. Strategic initiatives; 7.5.57. Zynex, Inc.; 7.5.57.1. Company overview; 7.5.57.2. Financial performance; 7.5.57.3. Product Benchmarking; 7.5.57.4. Strategic initiatives; 7.5.58. ZOLL Medical Corporation (Asahi Kasei Corporation); 7.5.58.1. Company overview; 7.5.58.2. Financial performance; 7.5.58.3. Product Benchmarking; 7.5.58.4. Strategic initiatives; 7.5.59. Össur (Embla Medical); 7.5.59.1. Company overview; 7.5.59.2. Financial performance; 7.5.59.3. Product Benchmarking; 7.5.59.4. Strategic initiatives; 7.5.60. Breg, Inc.; 7.5.60.1. Company overview; 7.5.60.2. Financial performance; 7.5.60.3. Product Benchmarking; 7.5.60.4. Strategic initiatives; 7.5.61. Bauerfeind USA, Inc.; 7.5.61.1. Company overview; 7.5.61.2. Financial performance; 7.5.61.3. Product Benchmarking; 7.5.61.4. Strategic initiatives

Pricing

Currency Rates

Single User Email from Publisher $6,950
Multi User License Fulfilled by Publisher $7,950
Global Site License Email from Publisher $9,950

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now